Investopedia: Drugs Have Moved J&J On To A New Phase

It took a while, but healthcare giant Johnson & Johnson (NYSE:JNJ) is once again delivering on its potential as a triple-threat in drugs, devices, and OTC consumer and health products. Strong growth in the drug and devices business is very much welcome, but now the question becomes whether management can lead a similar turnaround in OTC. Although J&J looks to be on the cusp of being a good buy, ongoing outperformance does seem predicated on a more well-rounded growth profile in the coming years.

Please continue reading here:
http://www.investopedia.com/stock-analysis/2012/Drugs-Have-Moved-JJ-On-To-A-New-Phase--JNJ-PFE-ABT-COV1017.aspx